Guggenheim Reaffirmed Purchase on GeneDx at October Finish, Lifted Value Goal to $170 After Q3 Beat

GeneDx Holdings Corp. (NASDAQ:WGS) is likely one of the greatest digital well being shares to purchase now.

On October 29, 2025, Guggenheim lifted GeneDx (NASDAQ:WGS) to a $170 value goal (Purchase) after the corporate’s blow-out Q3 announcement a day earlier. GeneDx had simply reported income of $116.7 million, up 52% 12 months over 12 months and roughly ~12% above Avenue; exome and genome income reached $98.9 million, up 65%, with exome/genome check volumes up 33%. Gross profitability widened too: adjusted gross margin improved to 74% (GAAP 72%), and adjusted internet revenue rose to $14.7 million.

Tonhom1009/Shutterstock.com

That print underpins Guggenheim’s call-outs, with exome and genome volumes nonetheless compounding, ASPs working increased, and gross margin trending up, therefore the larger goal. Administration additionally raised full-year 2025 steerage to $425–$428 million in income and 53–55% development in exome/genome income, alongside a 70–71% adjusted gross-margin information.

Crucially, Guggenheim addressed the 2026 spend feedback: even with stepping up opex subsequent 12 months, the agency doesn’t learn that as a return to adverse EPS, framing it as an alternative as funding towards a now-proven scale curve in pediatric and rare-disease genomics.

GeneDx Holdings Corp. (NASDAQ:WGS) makes a speciality of genomic testing, with a deal with whole-exome and whole-genome sequencing for pediatric and uncommon problems. Its choices additionally embody knowledge options that assist scientific decision-making and precision drugs.

Whereas we acknowledge the potential of WGS as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. Should you’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.

READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.

Disclosure: None.